Status:
RECRUITING
A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Collaborating Sponsors:
KU Leuven
Conditions:
Pneumonitis, Interstitial
Immunotherapy
Eligibility:
All Genders
18-120 years
Brief Summary
The main goal of this prospective non-interventional exploratory monocentric study is to characterize the immune cell composition of bronchoalveolar lavage (BAL) fluid from cancer patients experiencin...
Detailed Description
The investigators will apply single cell RNA- and TCR-sequencing on up to 5,000 single cells per sample. Additionally, cell surface protein expression can be integrated with the transcriptional inform...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Adult M/F/X (\>= 18 years)
- Patients receiving or having received treatment per guidelines
- Patients undergoing bronchoscopy with BAL, for possible cancer treatment-induced pneumonitis
- Not included in other clinical trials
- Signed informed consent form
- Exclusion criteria:
- • Collected material not suitable for further processing in this study (e.g. bad quality). This decision will be made in consultation with a lab technician and/or bio-informatician, specialized in single-cell analysis.
Exclusion
Key Trial Info
Start Date :
February 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04807127
Start Date
February 1 2020
End Date
January 31 2025
Last Update
July 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitaire Ziekenhuizen Leuven
Leuven, Flemish Brabant, Belgium, 3000